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Abstract
Manipulation of gene expression is an invaluable tool to study gene function in vitro and in vivo. The application
of small inhibitory RNAs to knock down gene expression provides a relatively simple, elegant, but transient
approach to study gene function in many cell types as well as in whole animals. Short hairpin structures
(shRNAs) are a logical advance as they can be expressed continuously and are hence suitable for stable gene
knockdown. Drug-inducible systems have now been developed; however, application of the technology has
been hampered by persistent problems with low or transient expression, leakiness or poor inducibility of the
short hairpin, and lack of reversibility. We have developed a robust, versatile, single lentiviral vector tool that
delivers tightly regulated, fully reversible, doxycycline-responsive knockdown of target genes (FOXP3 and
MYB), using single short hairpin RNAs. To demonstrate the capabilities of the vector we targeted FOXP3
because it plays a critical role in the development and function of regulatory T cells. We also targeted MYB
because of its essential role in hematopoiesis and implication in breast cancer progression. The versatility of this
vector is hence demonstrated by knockdown of distinct genes in two biologically separate systems.
Introduction
Conditional gene knockdown is a powerful tool for thestudy of gene function and is potentially therapeutic a
well. Systems for achieving this are constantly evolving. Short
hairpin RNAs (shRNAs) provide an elegant and relatively
straightforward approach for posttranscriptional down-
regulation of gene expression (Brummelkamp et al., 2002),
because unlike small interfering RNA (siRNA) these can be
stably expressed within the cell, and are not lost with cell
division. Drug-inducible activation of short hairpin RNAs
provides a more finely tuned approach to gene knockdown,
avoiding the artifacts that may result from constitutive gene
knockdown (Szulc et al., 2006). There are still problems,
however, in achieving effective and regulated knockdown by
shRNAs, associated particularly with poor inducibility of the
short hairpin (An et al., 2003), insufficient transcriptional ac-
tivity of cell-specific promoters (Liu et al., 2008), self-targeting
of the shRNA sequence (ter Brake and Berkhout, 2007; ter
Brake et al., 2008), transient knockdown of the target gene,
leakiness of short hairpin activity in the uninduced state
(Aagaard et al., 2007; Pluta et al., 2007), and lack of reversibility
(Ventura et al., 2004).
Lentiviral vectors are an appealing vehicle with which to
deliver genes or shRNAs, particularly because they are ca-
pable of transducing most nondividing or quiescent cells
(Naldini et al., 1996a). This is important for transfer into he-
matopoietic cells or other primary human cell types that are
typically refractory to transfection and are transduced inef-
ficiently by other types of virus (Naldini et al., 1996b; Salmon
et al., 2000; Barry et al., 2001). In addition, lentiviral vectors
offer several advantages over other viral vectors: they are
more efficient at delivering complex gene expression cas-
settes compared with other retroviral vectors (May et al.,
2000), they can mediate long-term gene expression (Seppen
et al., 2001), and they are relatively safe.
The biological targets used to validate the vectors for this
study were chosen because they are of clinical significance in
autoimmunity and cancer. In the first example we focused on
the transcription factor FOXP3 (forkhead box P3), the master
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transcription factor of regulatory T cells. Regulatory T cells
(Tregs) are essential for normal immune homeostasis, balanc-
ingpreventionof autoimmunity and immunepathologyon the
one hand, while simultaneously allowing effective immunity
to infection and tumors on the other. Many now regard these
cells as ‘‘master regulators’’ of immune responsiveness (Tang
and Bluestone, 2008). The forkhead transcription factor,
FOXP3, is expressed constitutively in ‘‘natural’’ CD4þ Tregs
and has been shown to be necessary and sufficient for mouse
Treg function (Bennett et al., 2001; Fontenot et al., 2003; Hori
et al., 2003; Yagi et al., 2004; Chang et al., 2005). Less is known
about the role human FOXP3 plays in the development and
function of the Treg (reviewed by Li and Greene, 2008).
To demonstrate the robustness of the vector, we also chose a
secondtarget, theMYBoncogene,whichencodesatranscription
factor (MYB). MYB is associated predominantly with normal
and leukemic hematopoiesis, based on its pattern of expression
(Gondaetal.,1982;Westinetal.,1982), theconsequencesof lossof
expression (Anfossi et al., 1989; Mucenski et al., 1991), and its
ability to induce leukemogenesis in several species (reviewed in
Ramsay and Gonda, 2008). MYB is also expressed at relatively
high levels inat least twoepithelial tumors: colon cancer (Torelli
et al., 1987) and breast cancer (Guerin et al., 1990). Evidence of a
causal role in carcinogenesis includes the correlation of expres-
sion level with poor prognosis (Biroccio et al., 2001) and the
presence of mutations that are likely to dysregulate MYB ex-
pression (Thompson et al., 1997; Hugo et al., 2006).
We describe here a lentiviral system able to knock down
target genes reversibly, using doxycycline (Dox) induction.
This system differs from previously described vectors as it
combines exquisite sensitivity to Dox with fast kinetics, ef-
ficient induction of shRNA expression, and reversibility in a
single lentivector. Vectors described in prior work (Szulc
et al., 2006; Aagaard et al., 2007; Pluta et al., 2007; Seibler et al.,
2007; Herold et al., 2008) do not combine all of these char-
acteristics in a single vector. We have used two biologically
distinct systems to model the robust gene-silencing capabil-
ity of this vector.
Materials and Methods
Vector construction
Third-generation lentiviral vectors containing the human
hepatitis virus posttranscriptional regulatory element (PRE)
and the HIV central polypurine tract (cPPT) element (de-
scribed in Barry et al., 2001) were used for all experiments.
For gene overexpression the backbone was reengineered to
contain the elongation factor (EF)-1a promoter (plvEIG), a
Gateway cloning site (att, CAT ccdB att), and an internal ri-
bosome entry site (IRES) to drive the marker gene encoding
green fluorescent protein (GFP). To generate the shRNAi
delivery vector (plv-T-sh), this backbone was engineered to
contain a Gateway cassette (att, CAT ccdB att) upstream of
the Rev-responsive element into which the shRNAi cassette
is recombined. The regulatory protein (T-REx) was inserted
under the control of the EF-1a promoter, and the marker
gene (GFP) is expressed from an IRES.
Short hairpin expression constructs
Five shRNA sequences predicted to knock down FOXP3
expression were designed, using BLOCK-iT RNAi designer
(Invitrogen, Carlsbad, CA). The following FOXP3 sequences
were chosen as potential shRNA targets and were numbered
with respect to FOXP3 cDNA numbering:
1355: GAGTCTGCACAAGTGCTTTGT
485: GCCACATTTCATGCACCAGCT
1289: CACACGCATGTTTGCCTTCTTC
767: GCTGGCAAATGGTGTCTGCAA
981: GCACTGACCAAGGCTTCATCT
Using the preceding target sequences, shRNA constructs
were generated in a sense–loop–antisense expression format,
using 9-mer TTCATGAGA to form the loop. A three-step
PCR procedure was used to generate the shRNA targeting
sequences. PCR primers were designed to generate two PCR
products: a 50 end with the attB1 site, tH1 promoter, sense
strand of the stem structure, and the loop; and a 30 end with
the loop, antisense strand of the stem structure, termination
signal, and attB2 site. In step 1, a 50 PCR product was gen-
erated with pBS-tH1, containing the tet-H1 promoter as
template DNA, an attB1 forward primer, and a site-specific
reverse primer (see later for primer sequences). In step 2, a 30
PCR product was generated with a site-specific forward
primer and an attB2 reverse primer (see later for primer se-
quences). In this reaction the forward and reverse primers
overlap and no template DNA was required. Products from
these two reactions were subsequently gel purified (QIA-
quick gel extraction kit; Qiagen, Hilden, Germany), quanti-
tated, combined, and used as the template in a third PCR
using the attB1 forward primer and the attB2 reverse primer.
The final PCR product was gel purified and inserted into the
pDONR entry vector as described subsequently.
Forward (50) and reverse (30) primers used to generate
shRNAs:
attB1 forward primer: GGGGACAAGTTTGTACAAAAA
AGCAGGCTT
attB2 reverse primer: GGGGACCACTTTGTACAAGAAA
GCTGGGTA
1355 forward primer: TGTTTCATGAGAACAAAGCACT
TGTGCAGA
1355 reverse primer: TGTTCTCATGAAACAAAGCACTT
GTGCAGA
485 forward primer: GCTTTCATGAGAAGCTGGTGCAT
GAAATGT
485 reverse primer: GCTTCTCATGAAAGCTGGTGCATG
AAATGT
1289 forward primer: GAATTCATGAGAAAGACTTCTT
CCGTTTGT
1289 reverse primer: GAATCTCATGAAAAGACTTCTTC
CGTTTGT
767 forward primer: CAATCTCATGAATTGCAGACAC
CATTTGCC
767 reverse primer: CAATTCATGAGATTGCAGACACC
ATTTGCC
981 forward primer: TCTTTCATGAGAAGATGAAGCC
TTGGTCAG
981 reverse primer: TCTTGTCATGAAAGATGAAGCCTT
GGTCAG
The Gateway technology (Invitrogen) universal cloning
system was used for the transfer of short hairpin expression
cassettes (FOXP3 and sh-b-catenin) and FOXP3 cDNA into
expression vectors. Short hairpin cassettes were inserted into
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a Gateway (Invitrogen)-compatible entry vector (pDONR),
using Gateway BP Clonase recombination techniques, and
transferred from the entry clone to the Gateway (Invitrogen)-
compatible lentiviral destination vector (plv), using Gateway
LR Clonase recombination techniques. FOXP3 lentiviral ex-
pression vectors were generated in a similar fashion, insert-
ing FOXP3 cDNA into lentiviral destination vector plvEIG.
All constructs were sequenced (BigDye terminator cycle se-
quencing kit, version 3.1; Applied Biosystems, Foster City,
CA) before use in experiments.
Cell culture
HEK293T cells were routinely cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (GIBCO; Invitrogen),
10% fetal calf serum (FCS; JRH Biosciences, Lenoxa, KA), 1%
penicillin–streptomycin (Pen/Strep), 1% l-glutamine, and
used between passages 11 and 20. Jurkat cells were routinely
cultured in RPMI (SAFC Biosciences, Lenoxa, KA), 10% FCS
( JRH Biosciences), 1% Pen/Strep, 1% l-glutamine and used
between passages 15 and 20. For transient transfection of
cells for Dual-Luciferase reporter assays, HEK293T cells were
seeded at a density of 1105 cells in 500 ml of medium
(DMEM–10% FCS–1% Pen/Strep, 1% l-glutamine) in a
24-well plate and transiently transfected with 25 ng of psi-
CHECK-2 vector and 775 ng of shRNA vector 4 hr later,
using Lipofectamine 2000 reagent (Invitrogen) and Opti-
MEM (Invitrogen) reduced serum medium, in accordance
with the standard protocol. For transient transfection of
Jurkat cells for Dual-Luciferase reporter assays, cells were
seeded similarly in 500 ml of medium (RPMI–10% FCS–1%
Pen/Strep, 1% l-glutamine) and transiently transfected with
Lipofectamine LTX reagent (Invitrogen) and Opti-MEM (In-
vitrogen) reduced serum medium. All transfections were
carried out in triplicate.
The human transformed malignant breast cancer line
MCF7, cultured in RPMI and transduced with the sh-Myb or
sh-SCR scrambled trigger sequence, were generated accord-
ing to the same protocols as described by Drabsch and col-
leagues (2007). GFP-positive cells were enriched by cell
sorting. Transduced cells were cultured in the presence or
absence of Dox (1mg/ml) for 48 hr unless otherwise stated.
Isolation and in vitro expansion of cord blood T cell
populations
Cord blood was obtained with informed maternal consent
as approved by the Children’s, Youth and Women’s Health
Service (North Adelaide, SA, Australia) Research Ethics
Committee. Mononuclear cells (MNCs) were isolated from
60 to 100ml of venous blood collected directly postpartum
into preweighed blood collection bags (Blood-Pack units;
Fenwal, Lake Zurich, IL) containing anticoagulant as previ-
ously described (Bresatz et al., 2007). Cord blood CD4þ
CD25þ cells (Tregs) and CD4þCD25 (helper T) cells were
isolated from MNCs, using a Dynabeads regulatory
CD4þCD25þ T cell kit (Invitrogen). The purity for each cell
type was routinely greater than 90% by two-color flow cy-
tometry for CD4 and CD25 expression. Cells were routinely
expanded for 8 days in the presence of Dynabeads human
T-expander CD3/CD28 (cat. no. 111-41D; Invitrogen) at a
bead-to-cell ratio of 3:1, before magnetic removal of the
beads. Ex vivo expansion of isolated T cell populations
(1106 cells per well in a 24-well plate) were performed in X-
VIVO 15 medium (BioWhittaker; Lonza, Basel, Switzerland)
supplemented with 20mM HEPES (pH 7.4), 5% heat-
inactivated pooled human serum (Lonza), 2mM l-glutamine,
and recombinant human interleukin-2 (rhIL-2, 500U/ml;
R&D Systems, Minneapolis, MN).
Proliferation assays
MCF7 cells previously transduced with plv-T-sh-Myb or
plv-T-sh-SCR were cultured in triplicate in the presence or
absence of Dox for 12 days. Cell proliferation was measure
by cell counting with a Coulter counter. Replicate samples
were also treated to wash out the Dox from day 5. In one
group of replicates of the sh-Myb-transduced cells, Dox was
washed out on day 5 and added back on day 7. Western
blotting was also carried out as described by Brabsch and
colleagues (2007).
Lentiviral packaging
To generate lentiviral stocks, HEK293T cells were seeded
at a density of 6106 cells in 18ml of medium in a 75-cm2
tissue culture flask. Cells were transfected with 12.5 mg of
transfer vector (plvEIG), 7.5 mg of Gag/Pol (D8.2), 6.25 mg of
Rev (pRSV-Rev), and 3.75 mg of Env (pCMV-VSV-G), using
Lipofectamine 2000 reagent (Invitrogen) and Opti-MEM
(Invitrogen) reduced serum medium, in accordance with the
standard protocol. The next day, the medium was replaced
with 10ml of fresh DMEM and 48hr later supernatant was
collected, filtered (pore size, 0.45 mm), and used immedi-
ately or stored frozen (–708C). Virus was concentrated by
ultracentrifugation at 22,000 rpm for 90min at 48C. The su-
pernatant was aspirated and the pellet was resuspended in
X-VIVO medium (1:25, v/v) to give a 25concentrated stock.
Virus was titered by limiting dilution, as described previ-
ously (Barry et al., 2001). Routinely we achieved titers of
5105–1106 transducing units per milliliter.
Lentiviral transduction
For transduction of cell lines, cells were routinely seeded
at a density of 3105 cells per well in a 6-well plate. Medium
was replaced with 3ml of viral supernatant (unconcentrated)
containing Polybrene at a final concentration of 5 mg/ml.
GFP-positive cells were sorted by flow cytometry (FACS-
Calibur; BD Biosciences, San Jose, CA). For transduction of
primary human cells 1–3105 CD4þCD25þ Tregs were
transduced with lentivirus at a multiplicity of infection
(MOI) of approximately 20, 24–48 hr after isolation. Cells
were expanded for 8 days in the presence of Dynabeads
before magnetic removal of the beads and isolation of GFPþ
cells and GFP cells by flow cytometry.
Intracellular staining
For detection of FOXP3 expression, cells (1105) were
washed in flow cytometry staining buffer (0.1% sodium
azide, 1% FCS, in phosphate-buffered saline) and stained
intracellularly with phycoerythrin (PE)-conjugated anti-
human FOXP3 antibody (PCH101; eBioscience, San Diego,
CA) using fixation/permeabilization and permeabilization
reagents (eBioscience) and standard protocols. Cells were
resuspended in fixation buffer (1% formaldehyde, 2%
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glucose, 0.02% sodium azide in phosphate-buffered saline)
and analyzed by flow cytometry (FACSCalibur; BD Bios-
ciences).
Purification of DNA and RNA
DNA was prepared with a QIAprep spin miniprep
kit (Qiagen) and HiSpeed plasmid midi purification kit
(Qiagen). RNA was prepared with an miRNeasy mini kit
(Qiagen).
Analysis of RNA expression by real-time PCR
RNA was reverse transcribed, using a QuantiTect reverse
transcription kit (Qiagen), and real-time PCR was performed
on a Rotor-Gene 6000 (Corbett Life Science/Qiagen), using a
FastStart Taq DNA polymerase kit (Roche, Indianapolis, IN)
and SYBR green fluorescent dye. Transcription factor mRNA
expression profiling was performed at various time points as
described in the figure legends, and cells were analyzed for
relative abundance of FOXP3 compared with an internal
control (b-actin).
FOXP3 forward: GAA ACA GCA CAT TCC CAGAGT TC
FOXP3 reverse: ATG GCC CAG CGG ATG AG
b-Actin forward: AAG AGC TAC GAG CTG CCT GAC
b-Actin reverse: GTA GTT TCG TGG ATG CCA CAG
Stem–loop reverse transcription-polymerase
chain reaction
Reverse transcriptase reactions were performed on 150 ng
of total RNA. First-strand complementary DNA (cDNA) was
synthesized with 0.05 mM stem–loop primer (SL-sh-1355) (50-
GTTGGCTCTGGTAGGATGCCGCTCTCAGGGCATCCTAC
CAGAGCCAACACAAAG-30) and 2mM antisense primer for
the reference gene hypoxanthine phosphoribosyltransferase
(Hprt-1) (50-CAGGCAAGACGTTCAGTCCT-30), using a Su-
perScript III reverse transcriptase kit (Invitrogen) according to
the manufacturer’s protocol. SL-sh-1355 contains a binding
site for a universal reverse primer (URevP; 50-GTAGGATG
CCGCTCTCAGG-30), a binding site for Universal Probe-
Library (UPL) probe #21 (Roche), and a six-base 30 overhang
sequence, which is complementary to the last six bases at the
30 end of sh-1355. Pulsed reverse transcription (RT) was car-
ried out under previously described conditions with modifi-
cations (Chen et al., 2005; Tang et al., 2006). Briefly, RNA was
initially incubated at 658C for 5min to uncoil the RNA. cDNA
synthesis was then performed at 168C for 30min followed by
60 cycles of 208C for 30 sec, 428C for 30 sec, and 508C for 1 sec.
A final incubation at 758C for 15min was performed to in-
activate the reaction. Additional RT-minus (i.e., without re-
verse transcriptase) reactions served as negative control.
For quantitative PCR, a 20-ml reaction containing 0.005
synthesized cDNA (from either an RT-positive or RT-minus
reaction), 1LC480 master probe mix (Roche), 250nM for-
ward primers (sh-1355 forward primer, 50-CGGCCGAGTC
TGCACAAGTG-30; Hprt-1 forward primer, 50-TGACCTTG
ATTATTTTGCATACC-30), 250 nM reverse primers (URevP,
Hprt antisense primers) (GeneWorks, Hindmarsh, SA, Aus-
tralia), 100 nM UPL probe #21 (for sh-1355), and 100 nM
probe #73 (for Hprt-1) (Roche) was prepared for each sample.
PCRs were performed with the LightCycler 480 system
(Roche) with a predenaturing step of 958C for 10min, and 45
cycles of 958C (10 sec), 608C (30 sec), and 728C (10 sec) fol-
lowed by a cooling step at 408C for 1min. Semiquantitative
PCR was performed with the exact reaction setup and con-
ditions for only 34–36 cycles without the presence of UPL
probe. The cycle threshold value (Ct) was calculated from the
amplification curve, using the second derivative maximum
method (Rasmussen, 2001) described with LightCycler 480
quantification software version 1.5 (Roche). To compare the
Ct value with gel electrophoresis results, we normalized the
value to Hprt-1, using the comparative Ct method.
Dual-Luciferase reporter assays
For luciferase assays, FOXP3 and b-catenin cDNAs were
inserted into the multicloning site of psiCHECK-2 (Promega,
Madison, WI) vector. psiCHECK-2 is a dual-luciferase re-
porter construct in which the cDNA of interest is cloned into
the 30 untranslated region (UTR) of the Renilla luciferase
gene. Renilla luciferase activity is normalized with respect to
firefly luciferase activity, which is carried on the same vector
to control for transfection efficiency. All constructs were se-
quenced (BigDye terminator cycle sequencing kit, version
3.1; Applied Biosystems) before use in experiments. Cells
FIG. 1. A single lentiviral expression
vector for drug-inducible knockdown of
FOXP3. (A) Diagrammatic representation
of the lentiviral vector design. The
plvEIG lentiviral vector provides the
backbone for this system. The short
hairpin expression cassette (tetracycline
minioperon fused to the H1 promoter
followed by the target stem–loop and a
terminator, pT) is inserted via Gateway
recombination downstream of the pack-
aging signal. An EF-1a promoter drives
transcription of the T-REx repression
cassette and an IRES is inserted upstream
of a GFP marker. (B) Schematic repre-
sentation of the PCR cloning strategy
used to generate the short hairpin cas-
settes, which are then recombined into
the Gateway vectors.
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were transiently transfected as described previously, be-
fore incubation in the absence or presence of doxycycline
(1 mg/ml). Subsequently, culture medium was removed and
cells were lysed with Dual-Luciferase reporter assay reagents
(Promega) according to the standard protocol. Samples were
assayed with luciferase assay reagent II (LAR II) and Stop &
Glo reagents and analyzed with a Veritas microplate lu-
minometer (Turner Biosystems/Promega).
Results
A single lentiviral vector to conditionally
knock down gene expression
A lentiviral vector was designed to achieve tightly reg-
ulated, drug-inducible knockdown of target gene expres-
sion. Short hairpin RNA expression cassettes generated by
PCR were inserted into the expression vector via donor
vector intermediaries, using Gateway technology. The
shRNA sequence was expressed from the tet operator–H1
promoter fusion (tH1) in either donor vector for validation
(pDONR), or transfer vectors for lentiviral delivery (plv-
T-sh). The T-REx repressor cassette transcribed from an
EF-1a promoter was included in the lentiviral back-
bone, thereby delivering all the components required for
tetracycline-induced derepression of shRNA transcription in
one vector. An internal ribosome entry site (IRES) down-
stream of the T-REx cassette was inserted for expression of
the marker gene GFP (Fig. 1A).
Cloning and screening of short hairpin RNAs
Construction of shRNA triggers, as cassettes with the tet
operator–H1 promoter fusion (tH1), facilitates the rapid
screening for functional shRNA molecules in the pDONR
vector before their transfer into the lentiviral backbone. A
panel of five 21-mer short hairpin sequences was designed
to knock down expression of human FOXP3 (BLOCK-iT
RNAi designer; Invitrogen). The Gateway adaptor tailed
tH1-shRNA cassettes generated by a two-step PCR (Fig. 1B)
were inserted into a pDONR vector and sequenced. To
screen for functional shRNA triggers, HEK293T cells were
transiently cotransfected with vectors constitutively ex-
pressing the short hairpin RNAs (pDONR-shRNA) and the
reporter vector psiCHECK-2 (Promega) carrying FOXP3
(psiCHECK-FOXP3). Functional shRNA triggers were then
identified by a reduction in Renilla activity from the psi-
CHECK-FOXP3 reporter. To confirm on-target specificity of
our short-hairpin sequences, a control b-catenin reporter
vector (psiCHECK-b-cat) and a validated b-catenin short
hairpin RNA (sh-b-cat) (van de Wetering et al., 2003) were
used in all experiments.
Screening of the predicted FOXP3 shRNA targeting se-
quences identified one trigger, sh-1355, that substantially
reduced (*40% knockdown) Renilla activity of the psi-
CHECK-FOXP3 reporter compared with cells transfected
with the reporter alone. No significant reduction in Renilla
activity was observed in cells cotransfected with psiCHECK-
FOXP3 and the sh-485, sh-767, or sh-981 expression vector,
whereas sh-1289, intriguingly, led to increased FOXP3 ex-
pression (60% higher) (means of triplicate samples and rep-
resentative of more than three experiments) (Fig. 2A). On-
target specificity was confirmed in cells cotransfected with
the b-catenin reporter vector (psiCHECK-b-catenin) and the
short hairpin b-catenin (sh-b-cat), where expression was
significantly reduced (80% knockdown) compared with cells
transfected with psiCHECK-b-catenin alone. In contrast, no
significant knockdown of Renilla activity was observed in
cells cotransfected with sh-1355 and the psiCHECK-b-catenin
reporter vector or in cells cotransfected with sh-b-cat and the
psiCHECK-FOXP3 reporter. This screening strategy allowed
rapid identification a single short hairpin RNA sequence (sh-
1355) able to specifically knock down expression of FOXP3.
FIG. 2. A short hairpin sequence is able to specifically and
inducibly knock down expression of FOXP3. (A) HEK293T
cells were transiently cotransfected with pDONR vector
containing one of five short hairpin sequences (sh-1355, sh-
485, sh-1289, sh-767, or sh-981) or control short hairpin sh-b-
catenin (sh-b-cat), and also with the FOXP3 reporter vector
(hatched columns) or b-catenin (b-cat) control reporter (open
columns). (B) HEK293T cells were transfected with b-catenin
control reporter vector and transduced with plv-T-sh-b-cat
(open columns) or with plv-T-sh-1355 (dotted columns) or
transfected with the FOXP3 reporter vector and transduced
with plv-T-sh-1355 (hatched columns). Cells were then in-
cubated with or without Dox. Labels denote the vector with
which the cells are transfected (abbreviated as FOXP3 or
b-cat), followed by the lentiviral vector (abbreviated as sh-
1355 or sh-b-cat). Results represent meansþ SD expressed
relative to the firefly luciferase control (n¼ 3).
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Conditional regulation of target genes
Next, we wished to demonstrate doxycycline-regulated
knockdown of our target genes. HEK293T cells transduced
with plv-T-sh-1355 and plv-T-sh-b-cat were then transiently
transfected with the psiCHECK reporter construct (psi-
CHECK-FOXP3 or psiCHECK-b-catenin) and doxycycline
(Dox) was added (1 mg/ml) to derepress shRNA transcrip-
tion. Knockdown of the reporter genes was monitored by
luciferase assay after 48 hr. Efficient and specific Dox-
dependent knockdown of reporter gene activity was ob-
served for both FOXP3 and b-catenin (Fig. 2B). In the absence
of Dox, cells transduced with plv-T-sh-1355 virus and
transfected with FOXP3 reporter vector (psiCHECK-FOXP3)
showed levels of Renilla activity comparable with that in cells
transfected with psiCHECK-FOXP3 alone (data not shown).
However, addition of Dox (1 mg/ml) substantially reduced
FOXP3 expression (>70% knockdown) (Fig. 2B). In contrast,
no change in Renilla activity was observed from the b-catenin
expression construct in cells transduced with plv-T-sh-1355
virus either in the absence or presence of Dox, indicating that
sh-1355 activity is specific. This result also indicates that
addition of Dox itself had no net effect on expression of the
target gene. Target-specific and Dox-inducible knockdown
was also observed with the plv-T-sh-b-cat-transduced cells
transfected with psiCHECK-b-catenin. Similar results were
observed in the Jurkat T cell line and NIH 3T3 cells for the sh-
b-cat vector (data not shown).
Lentivirally delivered FOXP3 is conditionally regulated
by sh-1355 in Jurkat T cells
The previous experiments have shown that short hairpin
RNAs could downregulate Renilla activity from a hybrid
mRNA containing FOXP3 or b-catenin sequences within its
30 UTR. In this mRNA the target gene sequences are not
translated. We therefore wished to determine whether sh-
1355 could conditionally downregulate the intact FOXP3
mRNA. To do this Jurkat cells, which do not express en-
dogenous FOXP3, were transduced with a lentivirus ex-
pressing FOXP3 from the EF-1a promoter (plvEIG-FOXP3)
and GFP from an IRES. Cells were sorted by flow cytometry,
into a population with the highest GFPþ expression (top 5%),
as compared with all GFPþ cells (pooled population)
(Fig. 3A). We confirmed that cells with the highest GFP
fluorescence also exhibited the highest levels of FOXP3
FIG. 3. Isolation of Jurkat cell lines expressing plvEIG-
FOXP3 and plv-T-sh-1135. (A) Jurkat cells were transduced
with plvEIG-FOXP3 virus and sorted on the basis of the in-
tensity of GFP fluorescence. Frequency histogram shows the
top 5% GFPþ (dashed line) isolated from the pooled popu-
lation of GFPþ cells (solid line) and GFP cells (gray line). (B)
Frequency histogram shows FOXP3 expression in the same
sorted populations of GFPþ cells. (C) Frequency histogram
shows the GFP levels in untransduced Jurkat cells (dotted
line), top 5% FOXP3-expressing cells (dashed line), and
FOXP3-positive cells superinfected with plv-T-sh-1135 (solid
line). Because both of these lentiviral vectors express GFP,
cells double transduced with plv-T-sh-1355 and plvEIG-
FOXP3 were isolated by gating on bright fluorescent GFPþ
signal, indicating the presence of both GFPþ lentiviral
vectors.
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expression by intracellular staining (Fig. 3B), suggesting that
the IRES-driven reporter was a robust marker of expression
of the target gene in plvEIG-FOXP3. The sorted population of
plvEIG-FOXP3 cells (top 5% GFPþ) was then transduced a
second time (superinfected) with plv-T-sh-1355 lentivirus. As
the levels of GFP in the superinfected cells were significantly
higher than in the single-transduced cells (Fig. 3C), a simple
gating strategy was used to analyze FOXP3 expression levels
in cells with the highest mean fluorescence intensity (MFI)
for GFP. Cells were treated with Dox (1mg/ml) for 48 hr,
stained intracellularly, and then analyzed by flow cytometry
for FOXP3 expression. We observed that the FOXP3 level in
cells transduced with both plvEIG-FOXP3 and plv-T-sh-1355
cultured in the absence of Dox was similar to that observed
in cells transduced with plvEIG-FOXP3 alone (Fig. 4A).
However, when Dox was added to the culture medium,
FOXP3 expression in the double-transduced cells was sig-
nificantly reduced, approaching the background levels of
staining observed in cells not expressing FOXP3 (Fig. 4A).
This result indicated that plv-T-sh-1355 downregulated
plvEIG-FOXP3 in a Dox-dependent manner in Jurkat popu-
lations expressing high levels of FOXP3. Real-time PCR
confirmed that FOXP3 mRNA expression was similarly
downregulated (Fig. 4B). The comparable levels of FOXP3
observed in cells transduced with plvEIG-FOXP3, and in
cells transduced with both plvEIG-FOXP3 and plv-T-sh-1355
cultured in the absence of Dox, is consistent with the tight
regulation of sh-1355 transcription by the T-REx protein in
the absence of derepression by Dox. This was confirmed by
highly sensitive stem–loop RT-PCR analysis of the expres-
sion of the plv-T-sh-1355 shRNA itself, showing no product
in empty Jurkat cells or Jurkat cells transduced with plv-T-
sh-1355 in the absence of Dox, but significant sh-1355 prod-
uct when the Jurkat cells transduced with plv-T-sh-1355 were
cultured in the presence of Dox (Fig. 4C).
FIG. 4. Conditional regulation of FOXP3 expression in
Jurkat cells and human Tregs. (A) Nontransduced Jurkat
cells, cells expressing plvEIG-FOXP3 alone (top 5%), and
cells coexpressing plvEIG-FOXP3 and plv-T-sh-1355 were
cultured in the absence or in the presence of Dox (1mg/ml)
for 48 hr. The frequency histogram shows intracellular
FOXP3 expression in untransduced Jurkat cells (gray dotted
line), cells expressing plvEIG-FOXP3 (top 5%) (gray solid
line), and cells expressing plvEIG-FOXP3 and plv-T-sh-1355,
in the presence (black dotted line) or absence (black solid
line) of Dox (1mg/ml). (B) FOXP3 mRNA expression levels
were determined by RT-PCR showing FOXP3 expression in
nontransduced Jurkat cells, cells expressing plvEIG-FOXP3
(top 5%), and cells expressing plvEIG-FOXP3 and plv-T-sh-
1355, in the presence (hatched columns) or absence (dotted
columns) of Dox (1mg/ml). (C) plv-T-sh-1355 RNA expres-
sion was determined by SL-RT-PCR. Amplicons from semi-
quantitative SL-RT-PCR were separated, using 3% agarose.
plv-T-sh-1355 and Hprt-1 RNA expression in nontransduced
Jurkat cells, cells expressing plvEIG-FOXP3, and cells ex-
pressing plvEIG-FOXP3 and plv-T-sh-1355, in the presence
and absence of Dox, are shown. (D) Isolated human Tregs
transduced with plv-T-sh-1355 were cultured in the presence
(dashed line) or absence (solid line) of Dox for 48 hr. Cells
were stained intracellularly with PE-conjugated anti-human
FOXP3 antibody.
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Regulation of FOXP3 in primary human Tregs
To test the broad scope of this lentiviral vector, we iso-
lated primary human cord blood Tregs (CD4þCD25þ) and
transduced them with plv-T-sh-1355 viral supernatant
(25concentrated). Transduced cells (mean transduction ef-
ficiency, 33.5%; n¼ 2) were then expanded ex vivo for 8 days
to increase cell numbers. Cells were sorted by flow cytometry
gating on GFPþ events. GFPþ and GFP cells were then
cultured in the absence or presence of Dox (1 mg/ml) for 48 hr
and subsequently stained intracellularly and analyzed by
flow cytometry for FOXP3 expression. We observed that
FOXP3 expression in Tregs transduced with plv-T-sh-1355
and cultured in the absence of Dox was similar to FOXP3
expression in nontransduced cells in the absence or presence
of Dox (data not shown). This result indicates that Dox has
no nonspecific effects on FOXP3 expression in non-
transduced cells and also, importantly, that plv-T-sh-1355 is
not leaky in the absence of Dox. When Dox was added to the
culture medium of plv-T-sh-1355-transduced Tregs, FOXP3
expression was reduced by 36.6% (MFI was reduced from
416 to 340Dox, respectively) compared with plv-T-sh-1355
Tregs cultured in the absence of Dox (Fig. 4D). These results
show that plv-T-sh-1355 conditionally downregulates the
expression of endogenous FOXP3 in human Tregs in the
presence of Dox.
Activation of short hairpin is both sensitive and rapid
A concentration curve to determine the kinetics of Dox in-
duction of sh-1355 activity to knock down expression of
FOXP3 was then generated. The results of this experiment
showed that the concentration of Dox routinely used, 1mg/ml,
far exceeds that which led to maximal FOXP3 knockdown
(between 20 and 40% FOXP3 remaining). At a Dox concen-
tration of 10ng/ml, FOXP3 expression was reduced to*40%
of that expressed in non-Dox-treated cells (Fig. 5A), indicating
the sensitivity of the system. Likewise, using SL-RT-PCR, we
observed no plv-T-sh-1355 shRNA in the absence of Dox but
robust expression in the presence of Dox at just 10 ng/ml (Fig.
5B), confirming the sensitivity of the system. Activation of the
short hairpin was also rapid. In the experiments described
here, cells were routinely treated with Dox for 48hr before
evaluating knockdown of FOXP3 expression, but we observed
partial knockdown of FOXP3 as early as 12hr after addition of
Dox (68% FOXP3 remaining) and maximal knockdown of
FOXP3 protein by 24hr (22% FOXP3 remaining) compared
with non-Dox-treated cells (Fig. 5C).
Gene regulation is robust and reversible
Having shown that target gene (FOXP3) expression can be
significantly downregulated in a Dox-dependent manner
with lentiviral sh-1355, we next wanted to test the revers-
ibility of the drug-induced knockdown of FOXP3 by per-
forming a washout experiment. Jurkat cells expressing high
levels of FOXP3 from plvEIG-FOXP3 and superinfected with
plv-T-sh-1355 were cultured in the presence or absence of
Dox (1 mg/ml) for 48 hr. After collecting an aliquot of cells
for analysis, the remaining cells were washed and returned
to culture. Over the next 120 hr, cells were collected every 24
or 48 hr, after which Dox was readded at 120 hr. As seen
previously, FOXP3 expression was reduced to *20% of
original levels after incubation with Dox (1mg/ml) for 48 hr
(Fig. 5D). After washout of Dox the level of FOXP3 expres-
sion remained at *20% for the next 48 hr, but increased at
each time point thereafter until FOXP3 had returned to
almost preknockdown levels (*90%) by 120 hr after Dox
removal. This result shows that drug-induced knockdown of
FOXP3 is efficient and reversible. To further test the ro-
bustness of the system, after the 120-hr time point Dox
(1 mg/ml) was added back and the cells were incubated for a
further 48 hr. FOXP3 expression dropped back down to 20%
of original levels (Fig. 5D). FOXP3 expression in cells con-
tinuously cultured in Dox for 120 hr remained low (3.8% of
nontreated cells; asterisk in Fig. 5D), indicating that Dox-
induced activation of the short hairpin is robust and pro-
longed. In all cases FOXP3 mRNA levels followed the same
expression pattern (Fig. 5E). Over the course of the washout
experiment, plv-T-sh-1355 shRNA expression exactly mir-
rored expression of FOXP3. Expression of this RNA was
high after 48 hr of Dox, but had diminished to near back-
ground levels after 120 hr of washout. plv-T-sh-1355 shRNA
levels increased once more when Dox was added back to the
cells. These results indicate that as the Dox is washed out,
plv-T-sh-1355 is concomitantly switched off and FOXP3 ex-
pression is derepressed (Fig. 5F and G).
Validation of reversible Tet-regulated gene
ablation in breast cancer cells
To rigorously establish the utility and reversibility of the
vector, we chose to target an endogenous cellular gene, the
oncogene MYB, in the breast cancer cell line MCF7. When a
prevalidated MYB-specific shRNA or a scrambled shRNA
(Drabsch et al., 2007) was delivered stably into MCF7 cells,
no impact on viability or growth characteristics was seen in
the absence of Dox, as measured in a proliferation assay.
However, when Dox was added to the culture at 1mg/ml, a
significant reduction in growth and proliferation was ob-
served only in the plv-T-sh-Myb-transduced cells. When
Dox was left with the cells for 5 days a stable gene-silencing
effect was observed at the level of both protein expression
and proliferation. This growth suppression was reversible,
as demonstrated by washout on day 5 and restoration of
growth kinetics. Furthermore, in the sh-Myb line only, the
growth inhibition could be reestablished by a second Dox
treatment on day 7, resulting in growth arrest for a second
time in the same culture (Fig. 6A). The impact of the sh-
Myb construct on MYB protein levels was confirmed by
Western blot analysis of the parent cell line, the cell line
transduced with sh-Myb, and two controls in which the
cells were transduced with a scrambled shRNA (sh-SCR)
or transduced with an empty lentiviral vector. In the plv-
T-sh-Myb-transduced MCF7 cells in the absence of Dox, the
levels of Myb were comparable to that of the parent cells or
the two controls. MYB was significantly reduced when Dox
was added, and returned to control levels after washout
(Fig. 6B).
Discussion
The main goal of this study was to build a simple, efficient
system with which to study gene function, and we chose two
genes to model this. Conditional gene knockdown has the
potential to be a powerful tool, with short hairpin RNAs
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FIG. 5. Activation of the short hairpin is sensitive, rapid, and reversible. (A) Jurkat cells transduced with both plvEIG-
FOXP3 and plv-T-sh-1355 were cultured in the presence of increasing concentrations of Dox for 48 hr, and intracellular
FOXP3 expression was determined by flow cytometry. (B) plv-T-sh-1355 RNA expression and control Hprt-1 RNA ex-
pression were determined by SL-RT-PCR. Amplicons from semiquantitative SL-RT-PCR were separated, using 3% agarose.
(C) Jurkat cells transduced with both plvEIG-FOXP3 and plv-T-sh-1355 were cultured in the presence of Dox (1 mg/ml) and
FOXP3 expression levels were analyzed over time. (D) Jurkat cells transduced with both plvEIG-FOXP3 (top 5%) and plv-T-
sh-1355 were cultured in the presence or absence of Dox (1 mg/ml) for 48 hr. After FOXP3 measurement, the remaining cells
were washed twice and returned to culture (labeled at 0 hr). At the times indicated cells were removed for quantification.
FOXP3 expression in cells transduced with plvT-sh-1355 was determined by the MFI of cells cultured in the absence of Dox
relative to the MFI of cells cultured in the presence of Dox. (E) Relative FOXP3 mRNA expression for the cells was determined
by calculating FOXP3 mRNA expression from cells cultured in the presence of Dox, relative to that in cells cultured in the
absence of Dox. (F) plv-T-sh-1355 RNA expression was determined by SL-RT-PCR. (G) Amplicons from semiquantitative SL-
RT-PCR were separated, using 3% agarose, and Ct values for plv-T-sh-1355 RNA were normalized with respect to Ct values
for control Hprt-1 and plotted.
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emerging as a highly effective and relatively straightforward
mechanism to achieve this goal. However, for this technol-
ogy to reach its full potential safe, efficient, and tightly reg-
ulated delivery systems need to be further developed.
A system that allows regulated control of gene expression
(including full reversibility) has huge advantages over sys-
tems that rely on absolute knockout or Cre-mediated exci-
sion (Ventura et al., 2004; Seidler et al., 2008), potentially
overcoming issues including lethality. It also allows knock-
down in the appropriate temporal- or stimulus-specific
manner. Of critical importance, developing such tools allows
for the controlled manipulation of gene expression in a va-
riety of primary cell types and diverse organisms, rather than
being restricted to mice. In addition, for a system to be ro-
bust, particularly for an in vivo model, manipulation of gene
expression should also be enduring.
There have been many advances in the design of gene
delivery systems, with lentiviruses emerging as a relatively
safe system of delivery (Bauer et al., 2008). We have based
the vectors described herein on the third-generation self-
inactivating lentiviral vectors first described and shared by
Trono and colleagues (Naldini et al., 1996a; Dull et al., 1998;
Salmon and Trono, 2007) and modified by us (Barry et al.,
2001). We, and others, have demonstrated that these lenti-
viral vectors have improved transduction efficiency, func-
tion, and specificity, particularly in primary cells (Taher et al.,
2008), and are also well tolerated in vivo (Seppen et al., 2001;
Yanay et al., 2003; Barry et al., 2005; Brzezinski et al., 2007),
making them ideal for in vivo studies. We chose to combine
the shRNA and regulatory elements into a single vector as
we believed that it is less practical to perform multiple
transductions or to generate clones when targeting rare pri-
mary cells or using in vivo models.
By using Gateway recombination technology we were
able to rapidly screen potential short hairpins before the
production of lentiviral particles. This is of potential benefit
as there are still persistent problems with short hairpin de-
sign, leading to inefficient knockdown of the target gene, and
thus requiring a number of targeting sequences to be tested
for each gene. Screening a bank of potential short hairpin
RNAs in this way revealed that one sequence out of five was
able to knock down target gene expression in a highly spe-
cific way.
In this paper we describe a single lentiviral vector capable
of delivering tightly regulated Dox-responsive knockdown
of target genes as shown by the regulated knockdown of two
different genes, FOXP3 and MYB, using single short hairpin
RNAs delivered into several different cell lines (HEK293T,
Jurkat, and MCF7). We also demonstrated regulated knock-
down of endogenous FOXP3 in primary human Tregs. In
contrast to the findings of ter Brake and Berkhout (2007),
who observed a substantial loss of shRNA activity in trans-
duced cells, we observed efficient knockdown of target genes
in either transfected or transduced cells.
Throughout our experiments we observed significant
knockdown of target genes (FOXP3, 60–95%; b-catenin, 80%;
and MYB, *80% knockdown, respectively), indicating effi-
cient expression and processing of the short hairpin cassettes.
This suggests that sufficient shRNA molecules can be pro-
duced from a single copy of the tet–H1 promoter shRNA
cassette in the viral backbone. We obtained high levels of
FOXP3 knockdown at an MOI of 1 in cell lines (MOI of 25 in
primary human Tregs), compared with others who have had
to use high viral titers or isolated cell clones to obtain robust
target knockdown with short hairpin RNAs (summarized in
Pluta et al., 2007). This compares favorably with results using
multiple copies of the short hairpin to achieve durable target
gene knockdown (ter Brake and Berkhout, 2007; ter Brake
et al., 2008). Significantly, the short hairpin RNA delivery
vector plv-T-sh described here appears not to be susceptible
FIG. 6. Validation of reversible gene silencing, using en-
dogenous target gene MYB. (A) The Myb-dependent growth
of the MCF7 cell line was confirmed by lentiviral delivery of
a validated sh-Myb construct (solid lines). Cells were cul-
tured without Dox (open circles), with Dox (solid circles),
after a single washout (solid diamonds), or after washout
and readdition of Dox (solid squares). Cells transduced with
a scrambled shRNA control (gray dashed lines) were also
treated without Dox (solid inverted triangles) or with Dox
(solid triangles). (B) The on-target effects of the lentiviral
sh-Myb were confirmed by Western blot (top), showing cells
with or without Dox, after washout, and after add-back of
Dox. A 1-mg/ml concentration of Dox was used for induc-
tion. Controls (scrambled shRNA and an empty vector) are
shown. Loading controls are shown by blotting with anti-b-
tubulin antibody (bottom).
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to inactivating mutations (ter Brake et al., 2008) as demon-
strated by the finding that MCF7 cells transduced with a
lentiviral construct encoding a validated MYB shRNA
(Drabsch et al., 2007) retains the ability to knock down MYB
oncogene levels even after prolonged culture in the absence
of Dox.
Importantly, in the absence of Dox the tet–H1 promoter
appears to be tightly regulated by the repressor protein, with
little evidence of leakiness. Not only was FOXP3 expression
in Jurkat cells transduced with plv-T-sh-1355, when cultured
in the absence of Dox, indistinguishable from that in parental
cells expressing FOXP3 alone, but importantly plv-T-sh-1355
RNA was detected (using the highly sensitive SL-RT-PCR
technique) only in cells treated with Dox. Similar observa-
tions were seen in MCF7 cells transduced with plv-T-sh-Myb
and importantly in primary human Tregs transduced with
plv-T-sh-1355 to knock down endogenous FOXP3. This has
been a hurdle in the development of inducible short hairpin
RNA technologies, where leakiness of shRNA expression has
been observed in both transfected and transduced cells
(Aagaard et al., 2007).
In experiments examining the kinetics of shRNAi induc-
tion, we show that this knockdown is both sensitive and
rapid. For example, plv-T-sh-1355 RNA was induced with
Dox at just 10 ng/ml and FOXP3 protein expression itself
could be reduced in the presence of Dox at 10 ng/ml,
100lower concentrations of Dox than routinely used, with
*60% knockdown of FOXP3 obtained and maximal re-
pression occurring from Dox at 25 ng/ml and onward. This
may be useful for in vivo experiments in which systemic
administration of Dox is required. Second, after induction
with Dox, derepression of the tet–H1 promoter-shRNA
cassette, initiation of transcription and processing of the
short hairpin must be rapid, because we observed partial
knockdown of FOXP3 protein by as early as 12 hr (68%
FOXP3 remaining) and maximal knockdown of FOXP3 by
24 hr (22% FOXP3 remaining) compared with non-Dox-
treated cells. This compares favorably with other systems in
which prolonged exposures to Dox (5 and 8 days) were
required for maximal knockdown at the protein level (Szulc
et al., 2006; Aagaard et al., 2007). One of the major strengths
of our system is that compared with others, our system is
fully and quickly reversible even when using high concen-
trations of Dox. In addition, washout of the Dox resulted in
loss of the plv-T-sh-1355 RNA with the concomitant gain of
FOXP3. Others show reversibility, but this is often incom-
plete or relatively slow and insensitive (Seibler et al., 2007;
Herold et al., 2008).
The vector described in this paper provides a simple,
single-vector system that is quickly and strongly inducible
and, in addition, fully reversible. We have carried out
carefully analyzed kinetics quantitating all of our results
with respect to appropriate controls to show convincingly
that the system described here is an advance on systems
currently available. This system is valuable not only as a
tool with which to study gene function, but also for mod-
eling human disease, and may represent a potential thera-
peutic modality.
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